Table 2.
Detailed patient treatment characteristics and clinical outcomes.
| Patient | Diagnosis | Age | Surgery | RT Dose (Gy)/No. of Fx | Chemo (TMZ) | Re-plan During RT (Fx No. at transition to re-plan; Reason) | No. of Fx on delivered on MRL | Acute Toxicity | Oncologic Outcomes |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GBM, IDH wild type | 32 | STR | 60/30 | Conc and Adj | Yes (15; tumor and edema progression) | 27 | Grade 2 headaches, nausea, fatigue | Died |
| 2 | GBM, IDH wild type | 65 | GTR | 60/30 | Conc and Adj | No | 29 | None | Died |
| 3 | GBM, IDH wild type | 62 | STR | 60/30 | Conc and Adj | No | 30 | None | Died |
| 4 | Astrocytoma, IDH mutant, WHO Grade 4 | 29 | STR | 60/30 | Conc and Adj | Yes (10; edema with midline shift) | 21 | Grade 2 headaches, nausea, fatigue | Stable Disease |
| 5 | Astrocytoma, IDH mutant, WHO Grade 3 | 36 | STR | 60/30 | Conc and Adj | No | 30 | None | Stable Disease |
| 6 | Oligodendroglioma, IDH mutant, 1p/19q co-deleted, WHO Grade 3 | 69 | STR | 59.4/33 | Adj | No | 32 | None | Stable Disease |
| 7 | Astrocytoma, IDH wild type, WHO Grade 3 | 42 | Biopsy | 60/30 | Conc and Adj | No | 30 | None | Progressed |
| 8 | GBM, IDH wild type | 57 | STR | 60/30 | Conc and Adj | No | 30 | None | Stable Disease |
| 9 | Astrocytoma, IDH wild type, WHO Grade 3 | 38 | STR | 54/30 | Conc and Adj | No | 29 | None | Progressed |
| 10 | Astrocytoma, IDH mutant, WHO Grade 4 | 34 | STR | 54/30 | Conc and Adj | Yes (15; edema) | 29 | Grade 1 headaches, nausea, fatigue | Stable Disease |
RT, Radiation; Fx, Fractions; TMZ, Temozolomide; MRL, high-field MR-Linac; GBM, Glioblastoma; STR, Subtotal resection; GTR, Gross total resection; Conc, Concurrent; Adj, Adjuvant.